Skip to content
Subscriber Only
Business
Prognosis

J&J Vaccine Provides Strong Shield Against Severe Covid

  • Shot shows 66% efficacy against disease in large global trial
  • Easier-to-store vaccine could reinvigorate immunization push
Video player cover image
J&J Covid Vaccine Is 66% Effective In Global Clinical Trial
Updated on

Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign.

In a study of more than 43,000 people, the vaccine prevented 66% of moderate to severe cases of Covid-19, according to a company statement Friday. And it was particularly effective at stopping severe disease, preventing 85% of severe infections and 100% of hospitalizations and deaths.